Close Menu

NEW YORK – Italian pharmaceutical company Menarini has announced plans to launch a new Phase Ib/II clinical trial evaluating MEN1611, the company's investigational PI3K inhibitor, in combination with the EGFR inhibitor cetuximab (Lilly's Erbitux) for patients with metastatic colorectal cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.